FY2025 · ended Dec 31, 2025 · Revenue $7.42M, -21.9% YoY · Filed Apr 14, 2026
BioNexus Gene Lab Corp. (BGLC) files with the SEC under industry code 8071, Services-Medical Laboratories. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $7.4 million and a net loss of $3.0 million. Free cash flow was -$1.9 million. As of Jun 30, 2026 it held $1.2 million in cash and investments and $198,585 in total debt.
Revenue (TTM)
$3.13M
-67.3% vs year-ago TTM
Net income (TTM)
$-2.58M
+12.2% vs year-ago TTM
Operating cash flow (TTM)
$-846,565
+71.3% vs year-ago TTM
Free cash flow (TTM)
$-853,600
EPS
$-0.09
Dividend per share
None
Shares outstanding
2.42M
-86.5% vs prior year
Net cash
$1.03M
as of Jun 30, 2026
Operating margin
-81.8%
FY 2026
Company profile
- Industry
- Services-Medical Laboratories (SIC 8071)
- Listed as
- BGLC (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- WY
- Headquarters
- Kuala Lumpur
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1737523
- Former names
- BioNexus Gene Lab Coporation (until May 8, 2020)
Other Services-Medical Laboratories companies
- Natera, Inc. NTRA
- Labcorp Holdings Inc. LH
- Quest Diagnostics Inc DGX
- Guardant Health, Inc. GH
- Caris Life Sciences, Inc. CAI
- GRAIL, Inc. GRAL
- RadNet, Inc. RDNT
- BillionToOne, Inc. BLLN
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $7.4M | $9.5M | $9.8M | $10.9M | $13.4M |
| Operating income | -$3.0M | -$1.6M | -$2.6M | -$291,177 | $1.1M |
| Net income | -$3.0M | -$1.6M | -$2.6M | -$355,966 | $751,571 |
| Diluted EPS | — | -$0.09 | — | — | — |
| Operating cash flow | -$1.8M | -$2.1M | -$1.8M | $551,822 | $9,161 |
| Free cash flow | -$1.9M | -$2.3M | -$2.0M | $551,822 | $5,999 |
| Total assets | $9.3M | $10.4M | $11.4M | $8.7M | $9.6M |
| Total liabilities | $637,856 | $2.1M | $1.7M | $2.1M | $2.4M |
| Stockholders' equity | $8.6M | $8.3M | $9.7M | $6.7M | $7.2M |
| Cash and investments | $2.5M | — | — | — | $2.1M |
| Total debt | $176,046 | $210,557 | $133,395 | $56,775 | $76,947 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
|
Oct 7, 2026 | Oct 5, 2026 |
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Other events
|
Jul 28, 2026 | Jul 28, 2026 |
| 8-K |
Current report
Other events
|
Jun 5, 2026 | May 29, 2026 |
| 10-Q | Quarterly report | May 15, 2026 | Mar 31, 2026 |
| 10-K | Annual report | Apr 14, 2026 | Dec 31, 2025 |
All 157 BioNexus Gene Lab Corp. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.